LOXL2 and breast cancer: In addition to small-molecule inhibitors, another LOXL2 inhibitor is the patented de primary amino-containing diazocynonane compound, which was tested in a transgenic mouse model of breast cancer and shown to availably reduce lung metastasis formation.